Does Rallies show JAZZ 10-K and 10-Q filings?

Rallies organizes JAZZ SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.

Is JAZZ research on Rallies investment advice?

No. Rallies provides research, data, and educational context for JAZZ. It does not provide personalized investment advice.

JAZZ (Jazz Pharmaceuticals, Inc.) Stock Analysis - SEC Filings

Jazz Pharmaceuticals, Inc. (JAZZ) is a publicly traded Healthcare sector company. As of May 21, 2026, JAZZ trades at $237.51 with a market cap of $14.40B and a P/E ratio of 26.45. JAZZ moved +0.70% today. Year to date, JAZZ is +37.05%; over the trailing twelve months it is +115.29%. Its 52-week range spans $95.49 to $242.18. Analyst consensus is strong buy with an average price target of $241.43. Rallies surfaces JAZZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find JAZZ SEC filings?

Rallies organizes JAZZ SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

JAZZ Key Metrics

Key financial metrics for JAZZ
Metric	Value
Price	$237.51
Market Cap	$14.40B
P/E Ratio	26.45
EPS	$9.06
Dividend Yield	0.00%
52-Week High	$242.18
52-Week Low	$95.49
Volume	36
Avg Volume	0
Revenue (TTM)	$4.07B
Net Income	$560.12M
Gross Margin	0.00%

Latest JAZZ News

Jazz Pharmaceuticals jumps on Q1 revenue surge, EPS beat, and reaffirmed 2026 outlook — May 6, 2026
Jazz Pharmaceuticals Reports 19% Revenue Growth to $1.1B, Zanidatamab Granted Priority Review — May 5, 2026
Jazz Pharmaceuticals rises as ASCO 2026 Ziihera data looms, analyst optimism builds — Apr 27, 2026
Jazz Pharmaceuticals Gets FDA Priority Review, August 25 PDUFA for Ziihera in HER2+ GEA — Apr 27, 2026
Jazz Pharmaceuticals Sets May 5 Q1 Report, Showcases ASCO Data for Ziihera and Zepzelca — Apr 21, 2026

Recent JAZZ Insider Trades

COZADD BRUCE C sold 6.00K (~$1.22M) on May 1, 2026.
COZADD BRUCE C sold 3.68K (~$700.78K) on Apr 1, 2026.
COZADD BRUCE C sold 2.29K (~$437.63K) on Apr 1, 2026.

JAZZ Analyst Consensus

15 analysts cover JAZZ: 0 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $241.43.

Common questions about JAZZ

Where can I find JAZZ SEC filings?: Rallies organizes JAZZ SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show JAZZ 10-K and 10-Q filings?: Rallies organizes JAZZ SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is JAZZ research on Rallies investment advice?: No. Rallies provides research, data, and educational context for JAZZ. It does not provide personalized investment advice.